Expert Interviews

A diabetes expert investigates the personal factors impacting patients' adoption of diabetes devices and technologies, while concurrently exploring specific plan policies, wellness initiatives, and benefit designs that could most effectively and equitably enhance diabetes outcomes across diverse demographic groups.

Focusing on the future treatment landscape of atopic dermatitis, Dr Eichenfield discusses current unmet needs and highlights standout studies and presentations from the 2024 AAD Annual Meeting.

Lawrence Eichenfield, MD, provides clinical insights on evaluating patient response to therapy and managing adverse effects.

A diabetes expert examines how digital devices, virtual care access, and medication therapies can enhance convenience, outcomes, and cost-effectiveness in diabetes management, spotlighting the transformative potential of continuous glucose monitors to empower patients and elevate the quality of patient care.

David Hines underscores the criticality of routine monitoring for members with diabetes, encompassing glycemic control, blood pressure, and cholesterol levels, while simultaneously highlighting the indispensable nature of patient buy-in, engagement in daily self-management routines, and access to educational resources to bridge prevalent knowledge deficits, all geared towards optimizing diabetes care.

An expert on the treatment of atopic dermatitis provides insights on navigating insurance barriers and discusses how managed care organizations can incentivize and support the implementation of evidence-based guidelines and best practices across healthcare settings.

An expert dermatologist outlines factors that influence treatment selection for patients with atopic dermatitis and discusses how often patients need systemic therapy, given the available topical therapy options.

Veteran healthcare lobbyist discussed the prospects for the Senate passing comprehensive PBM legislation in the most recent episode of Managed Healthcare's DC Roundtable podcast.

A diabetes expert investigates how comorbidities like obesity, hypertension, hyperlipidemia, and depression impede effective diabetes management, while concurrently exploring potential health plan benefits that could synergistically address these coexisting conditions to improve overall care.

David Hines examines the profound impact of social determinants like food insecurity, housing instability, and limited access to healthcare services on the health outcomes of individuals with diabetes, while also delving into the multifaceted barriers hindering effective diabetes management and offering insights to overcome these challenges.

Gabriela Hobbs, MD, and Timothy Mok, PharmD, BCPS, BCOP, close the discussion with key takeaways for payers to consider related to ruxolitinib and insights on future research.

A KOL considers how health care providers can enhance patient understanding of Demodex blepharitis and issues surrounding treatment adherence.

Dr Eichenfield provides a comprehensive overview of topical and systemic treatments available for the treatment of patients with atopic dermatitis.

Lawrence Eichenfield, MD, discusses how the treatment landscape for atopic dermatitis has changed in recent years and provides clinical insights on the clinical burden and most burdensome symptoms of the disease.

Selina McGee, OD, FAAO, evaluates the cost and efficacy of in-office procedures like microblepharoexfoliation, the potential clinical and economic costs associated with delaying access to the FDA-approved treatment through prior authorization or mandating prior use of traditional over-the-counter therapies like tea tree oil and lid wipes, and considers impact on patient adherence.

Following a review of the safety analysis of MAJIC-PV, the panel discusses the main limitations and key takeaways from the study.

A comprehensive overview of key findings from the MAJIC-PV trial investigating ruxolitinib in patients with polycythemia vera, highlighting efficacy and symptom improvement.

A key opinion leader examines the historical context of Demodex blepharitis treatment, discussing the efficacy and limitations of previous therapies, and emphasizes a recently FDA-approved therapy that directly targets Demodex mites, leading to improved efficacy compared to treatments that only address symptoms.

Gabriela Hobbs, MD, describes characteristics of the patient population included in the MAJIC-PV study, and analyzes best available therapies received in the comparator arm.

Experts on polycythemia vera provide a comprehensive overview of the objectives and study design of the MAJIC-PV clinical trial, highlighting key endpoints.

Selina McGee, OD, FAAO, examines the prevalence, primary symptoms, quality of life impact, and the issues of underdiagnosis and misdiagnosis surrounding Demodex blepharitis in the United States.

Gabriela Hobbs, MD, provides an overview of the role of ruxolitinib in treating patients with hydroxyurea-resistant or hydroxyurea-intolerant polycythemia vera.

Timothy Mok, PharmD, BCPS, BCOP, and Gabriela Hobbs, MD, introduce themselves and provide insights on the prevalence of hydroxyurea resistance or intolerance in patients with polycythemia vera (PV) and how it impacts treatment decisions and costs.

Mahsa Salsabili, PharmD, PhD, explores risk and value-based contracting for prescription digital therapeutics, along with strategies for manufacturers to support their utilization and optimization, while also delving into cost-effectiveness modeling and budget impact analysis.

Mahsa Salsabili, PharmD, PhD, offers a comprehensive list of factors for healthcare providers and payers to consider in order to streamline the process of prescription digital therapeutics to patients.

Physician shortages and retail pharmacy closures are creating areas without access to healthcare in rural regions and inner cities, warns Luke Greenwalt, vice president, market access, at IQVIA.

Newly launched drugs coming are facing payer controls and other hurdles, says Luke Greenwalt, vice president, market access, at IQVIA.